Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Early Phase 1
3(100.0%)
3Total
Early Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06163274Early Phase 1Terminated

Trial to Assess Acceptability and Safety of Two Placebo Intravaginal Rings

Role: collaborator

NCT03255915Early Phase 1Unknown

PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)

Role: lead

NCT02431273Early Phase 1Completed

Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women

Role: collaborator

All 3 trials loaded